UCL Confidence in Concept 2013
Lead Research Organisation:
University College London
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
People |
ORCID iD |
Publications
Bayle E
(2017)
4-Cyano-2-methoxybenzenesulfonyl Chloride
in Organic Syntheses
Igoe N
(2017)
Design of a Chemical Probe for the Bromodomain and Plant Homeodomain Finger-Containing (BRPF) Family of Proteins.
in Journal of medicinal chemistry
Igoe N
(2017)
Design of a Biased Potent Small Molecule Inhibitor of the Bromodomain and PHD Finger-Containing (BRPF) Proteins Suitable for Cellular and in Vivo Studies.
in Journal of medicinal chemistry
Maini AA
(2016)
A Comparison of Human Neutrophils Acquired from Four Experimental Models of Inflammation.
in PloS one
Meier JC
(2017)
Selective Targeting of Bromodomains of the Bromodomain-PHD Fingers Family Impairs Osteoclast Differentiation.
in ACS chemical biology
Pengo N
(2018)
Identification of Kinases and Phosphatases That Regulate ATG4B Activity by siRNA and Small Molecule Screening in Cells.
in Frontiers in cell and developmental biology
Sofokleous P
(2017)
Sustained antimicrobial activity and reduced toxicity of oxidative biocides through biodegradable microparticles.
in Acta biomaterialia
Tsefou E
(2021)
Investigation of USP30 inhibition to enhance Parkin-mediated mitophagy: tools and approaches.
in The Biochemical journal
| Description | Day - TIPS microparticles |
| Amount | £250,000 (GBP) |
| Organisation | AGA Nanotech Ltd |
| Sector | Private |
| Country | United Kingdom |
| Start | |
| Description | Eisai Funding Kettler project |
| Amount | £314,480 (GBP) |
| Organisation | Eisai Ltd |
| Sector | Private |
| Country | Japan |
| Start | 09/2016 |
| End | 12/2018 |
| Description | Gamma Healthcare - Day |
| Amount | £198,000 (GBP) |
| Organisation | Gamma Healthcare |
| Sector | Private |
| Country | United States |
| Start | 07/2015 |
| End | 07/2016 |
| Description | Identification of small molecule activators of mitophagy |
| Amount | £375,355 (GBP) |
| Organisation | Eisai Ltd |
| Sector | Private |
| Country | Japan |
| Start | 05/2020 |
| End | 04/2022 |
| Description | LiDo Studentship Award -O'Brien |
| Amount | £79,967 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | MRC Project Grant, Alastair O'Brien |
| Amount | £460,940 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 08/2020 |
| Description | PharmAlliance, Mazzon |
| Amount | £20,000 (GBP) |
| Organisation | University College London |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2016 |
| End | 09/2016 |
| Description | Small Molecule activators of autophagy - extension |
| Amount | £169,579 (GBP) |
| Organisation | Eisai Ltd |
| Sector | Private |
| Country | Japan |
| Start | 10/2019 |
| End | 03/2020 |
| Description | Targeting autophagy dependence in pancreatic cancer |
| Amount | £109,341 (GBP) |
| Funding ID | 2018RIF_15 |
| Organisation | Pancreatic Cancer UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2019 |
| End | 09/2022 |
| Description | UCL Technology Fund - Fish |
| Amount | £70,000 (GBP) |
| Organisation | UCL Business |
| Sector | Private |
| Country | United Kingdom |
| Start | |
| Description | UCL Technology Fund - Gaspar |
| Amount | £1,000,000 (GBP) |
| Organisation | UCL Business |
| Sector | Private |
| Country | United Kingdom |
| Start | |
| Description | UCL Technology Fund, Fish |
| Amount | £75,000 (GBP) |
| Organisation | UCL Business |
| Sector | Private |
| Country | United Kingdom |
| Start | 01/2016 |
| End | 12/2016 |
| Description | UCLH BRC (SBC) grant - Day |
| Amount | £140,000 (GBP) |
| Organisation | National Institute for Health Research |
| Department | NIHR Biomedical Research Centre |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Wellcome Trust Clinical Training Fellopwship - O'brien/George |
| Amount | £273,288 (GBP) |
| Organisation | Wellcome Trust |
| Department | Wellcome Trust Research Training Fellowship |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2015 |
| End | 09/2018 |
| Description | Gale CiC Collaboration with GSK |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | Project proposal around the development of notch pathway modulators in the treatment of hearing loss. Project team provides theoretical, technical and practical disease biology expertise. |
| Collaborator Contribution | In vitro compound screening and provision of modulator compounds |
| Impact | Project completed disproving published literature data. The collaboration continues through the appointment of Rick Cousins (GSK) as a visiting professor to UCL. |
| Start Year | 2015 |
| Description | Holmes CiC collaboration with Evotec |
| Organisation | Evotec |
| Country | Germany |
| Sector | Private |
| PI Contribution | Developed project proposal and plan. Provided theoretical and practical disease expertise. |
| Collaborator Contribution | Provided high quality primary screening, medicinal chemistry and xray crystallography |
| Impact | Collaboration led to the development of a Wellcome Trust SDDI application that had to be withdrawn at the full stage due to illness. The project team is seeking alternative approaches to exploiting the data package generated. Multi-disciplinary - Chemistry, cheminformatics, biology, structural biology, clinical. |
| Start Year | 2015 |
| Description | Mookerjee CiC collaboration with Medimmune |
| Organisation | AstraZeneca |
| Department | MedImmune |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Development of research project proposal and plan. Disease and biology expertise. |
| Collaborator Contribution | Generation and scaled up preparation of a key rat isoform of the LCAT protein needed in the project. |
| Impact | Agreement with Medimmune to supply protein |
| Start Year | 2015 |
| Description | Nathwani CiC collaboration with Puridify |
| Organisation | Puridify |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Development of the project proposal and plan. Theoretical, technical and practical biological and disease expertise. |
| Collaborator Contribution | Technical expertise in the production and purification of AAV vectors |
| Impact | Too early to be specific |
| Start Year | 2015 |
| Title | Angiogenic Factors |
| Description | The disclosure relates to methods for obtaining angiogenic factors, as well as to methods of treating cardiovascular disease and methods for stimulating angiogenesis. |
| IP Reference | US2018028570 |
| Protection | Patent application published |
| Year Protection Granted | 2018 |
| Licensed | No |
| Impact | none to date |
| Title | MUSCLE CONDITIONING DEVICE |
| Description | The present invention relates to a muscle conditioning device comprising one or more implantable bodies and an actuator, where in use, the implantable bodies are magnetically coupled to the actuator and are resiliently positionable to administer mechanical strain to the muscle on operation of the actuator. It also relates to individual elements of the device; to compositions and kits thereof; and to uses of and methods involving the device. |
| IP Reference | WO2014091182 |
| Protection | Patent application published |
| Year Protection Granted | 2014 |
| Licensed | No |
| Impact | Too early |
| Title | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS |
| Description | The present invention provides compounds of formula (I) as described herein and pharmaceutically acceptable salts, hydrates and solvates thereof for use in medicine, for example in the treatment of acute myeloid leukaemia: |
| IP Reference | WO2016034512 |
| Protection | Patent application published |
| Year Protection Granted | 2016 |
| Licensed | No |
| Impact | too early |
| Title | THERAPEUTIC AGENTS AND DELIVERY WITH MICROSPHERES |
| Description | TIPS loaded with therapeutic entities |
| IP Reference | EP3089738 |
| Protection | Patent application published |
| Year Protection Granted | 2016 |
| Licensed | No |
| Impact | none to date |
| Title | THERAPEUTIC AGENTS AND DELIVERY WITH MICROSPHERES |
| Description | The invention relates to methods for attaching therapeutic agents to structures produced by thermally induced phase separation as well as methods for coating devices and producing multi-layered microspheres. |
| IP Reference | WO2015097464 |
| Protection | Patent application published |
| Year Protection Granted | 2015 |
| Licensed | No |
| Impact | none to date |
| Title | TREATMENT |
| Description | The present invention relates to the prevention and/or treatment of lysosomal storage diseases in a patient. |
| IP Reference | US2017173184 |
| Protection | Patent application published |
| Year Protection Granted | 2017 |
| Licensed | Yes |
| Impact | Licensed to Orchard Tx |
| Title | TREATMENT AND/OR PREVENTION OF LYSOSOMAL STORAGE DISEASES |
| Description | The present invention relates to the prevention and/or treatment of lysosomal storage diseases in a patient. |
| IP Reference | WO2017103612 |
| Protection | Patent application published |
| Year Protection Granted | 2017 |
| Licensed | Yes |
| Impact | licensed to Orchard Tx |
| Company Name | Orchard Therapeutics Ltd |
| Description | Orchard Therapeutics is a biotechnology company incorporated in September 2015 and dedicated to bringing transformative gene therapies to patients with serious and life-threatening orphan diseases Our programmes will use the potential of ex-vivo autologous haematopoietic stem cell gene therapy to restore normal gene function in severe and life-threatening inherited disorders We work in partnership with the world's leading research centres to harness the life-giving potential of gene therapy Our mission is to translate results from pre-clinical and early clinical research into commercially approved gene therapies for patients around the world |
| Year Established | 2015 |
| Impact | Currently have one program in clinical development aiming to submit for marketing approval 2018/19 |
| Website | http://orchard-tx.com/ |
| Company Name | Virology Research Services |
| Description | Virology Research Services was founded by scientists at University College London to share world-leading resources and expertise with industry and academia, aiming to help combat infectious diseases. Our focus is preclinical studies and viral biology, where we provide rigorous, original, and cost-effective solutions to the early stages of R&D. We help companies and academics explore new antiviral treatments, investigate the biology of viral infection, and test pathogen response to treatment. |
| Year Established | 2018 |
| Impact | Virology Research Services (VRS) was awarded a £25k MRC Proximity to Discovery Industry Engagement Fund for knowledge exchange with The Native Antigen Company (TNAC, LINK), a group focused on the expression and purification of viral antigens, and of antibodies targeting viral proteins. Most antibodies against viral proteins, particularly for emerging viruses, tend to be well characterised in biochemical assays; however, a thorough characterisation for immunofluorescence (IF) is often lacking. This represents a concern for scientists interested in image-based applications, who may need to test and optimise several antibodies before identifying a suitable one. Making use of the extensive virology and imaging expertise at VRS, and of the state-of-the-art high-throughput and microscopy facilities at UCL, the aim was to develop high- and low- throughput protocols for different antibodies, validate their specificity across viruses of the same family, and generate informative pictures as a reference. This successful collaboration which resulted in a full characterisation of TNAC's Antibodies and has been reported on the companies website: https://thenativeantigencompany.com/new-immunofluorescence-data-for-flavivirus-antibodies/ |
| Website | http://virologyresearchservices.com/ |